Complete, durable remission in a patient with no remaining standard treatment options is among the rarest and most instructive events in oncology — and this case, verified over a decade through repeated biopsies and autopsy, challenges assumptions about what trace-element pharmacology can do when combined with conventional cytotoxic agents.
The report documents a patient with advanced squamous-cell lung cancer who had already failed chemotherapy, radiotherapy, and targeted therapy before enrolling in the SECAR phase I trial evaluating high-dose intravenous sodium selenite. Following selenite infusion per protocol, the patient received gemcitabine plus carboplatin. Initial imaging indicated only stable disease, but clinical improvement emerged and tumor regression followed gradually. By 2011, FDG-PET/CT confirmed no residual tumor. Serial bronchial and stent biopsies between 2014 and 2017 found no malignancy, and autopsy tissue harvested approximately ten years after treatment confirmed complete absence of cancer — a verification standard almost never achievable in oncology outcome data. Retrospective biomarker analysis revealed strong membranous PD-L1 expression in the pre-treatment biopsy alongside a progressive decline in plasma soluble PD-L1 from 93 pg/mL before selenite to 38 pg/mL twelve weeks after chemotherapy completion.
Sodium selenite at pharmacological doses generates reactive oxygen species selectively toxic to cancer cells and has demonstrated pro-apoptotic effects in vitro and in animal models, but human evidence has remained anecdotal. The PD-L1 dynamics here are mechanistically intriguing: selenite may have modulated the tumor immune microenvironment in ways that sensitized the cancer to subsequent chemotherapy — a sequence-dependent effect that warrants formal investigation. Critically, this is a single case report. No causal inference is possible, spontaneous remission cannot be excluded, and the SECAR trial was phase I, designed for safety rather than efficacy. Nevertheless, the decade-long autopsy-confirmed cure combined with longitudinal biomarker data elevates this beyond typical anecdote and makes a compelling argument for selenite's inclusion in hypothesis-driven combination immunology trials.
